Weight-loss drugs may also reduce cancer risk, research suggests

A growing body of research indicates that popular weight-loss drugs, such as Ozempic and Wegovy, might also play a role in treating or preventing specific types of cancer. This potential benefit is the latest in a series of unexpected advantages linked to GLP-1 medications, which have seen a significant rise in usage, now being taken by one in eight adults in the United States.

William Brangham of the PBS NewsHour reports on this developing area of study. The GLP-1 class of drugs, initially developed for managing type 2 diabetes, has gained widespread attention for its effectiveness in weight management. However, emerging scientific evidence points towards a broader therapeutic potential.

While the exact mechanisms are still under investigation, researchers are exploring how these drugs might influence cancer development and progression. The findings suggest a promising new avenue for cancer prevention and treatment, adding to the drug class's already impressive profile.